FOX 13 Investigation: Florida Synthetic Kratom Makers Created MGM-15 to Evade the 7-OH Ban

Why it matters

Synthetic kratom manufacturers responded to Florida's 7-OH ban by engineering a replacement compound called MGM-15, which killed at least one person before regulators caught up. This chemical whack-a-mole pattern has direct implications for the federal scheduling now taking effect August 5.

The big picture

When Florida declared 7-hydroxymitragynine a Schedule I narcotic in June 2025, manufacturers did not stop — they reformulated. MGM-15, a closely related derivative, appeared on shelves within months. Florida's emergency rule now explicitly covers MGM-15 and two other analogue compounds. Federally, the DEA's temporary scheduling of 7-OH takes effect today, raising urgent questions about whether the same evasion cycle will play out nationwide.

Key findings

• Florida banned 7-OH in June 2025 as a Schedule I narcotic; manufacturers responded by synthesizing MGM-15, a structural analogue
• Hernando County resident Michael Walker died from MGM-15 ingestion alongside other synthetic kratom compounds, confirmed by medical examiner toxicology
• Florida extended its emergency rule to cover MGM-15 and two additional derivatives found in Walker's autopsy within two weeks of the death report
• Poison Control Centers received 3,434 kratom-related reports in 2025, up from 258 in 2015 — a 1,200% increase over 10 years
• FDA Commissioner Dr. Marty Makary called 7-OH scientifically equivalent to an opioid, saying it binds to the mu-receptor and warning that regulatory failure mirrors the fentanyl crisis

What they say

"7-OH binds to the mu-receptor, which means scientifically, by definition, it is an opioid... It is scientifically meeting criteria of an opioid and yet you can go in a vape shop on any corner and buy it like a cup of coffee. We have to be proximate to this. We got burned with fentanyl and prescription drugs; we cannot be behind the 8 ball again," said FDA Commissioner Dr. Marty Makary.

Bottom line

Banning individual synthetic kratom compounds without addressing analogue manufacturing creates a lethal loop — Florida proved it, and the federal DEA scheduling taking effect today faces the same structural challenge.